Overview
An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.
Eligibility
Inclusion Criteria:
- prostate adenocarcinoma verified by at least 12 core biopsy
- patient must understand the sense of research, agree to participate and sign a form of agreement
- low oncological risk according to EAU (European Association of Urology) Guidelines: stage T1-T2a, PSA<10 ng/ml, ISUP (International Society of Urological Pathologists score)=1 (Gleason score 3+3=6)
- not more than 33% cores with adenocarcinoma
Exclusion Criteria:
- previous treatment of prostate cancer
- other prostatic malignant neoplasms
- other oncological diseases
- treatment with 5-alfa-reductase inhibitors
- patient's refuse to continue study
- patient's desire to begin treatment